What's Happening?
CraniUS Therapeutics LLC, a neurotechnology company based in Baltimore, has successfully raised $20 million in Series B financing. This funding is aimed at accelerating the development of their NeuroPASS
platform, a fully implantable, skull-embedded device designed to bypass the blood-brain barrier (BBB) for targeted drug delivery and monitoring in the brain. The NeuroPASS platform is being developed as a multi-product system intended to transform cranial implants from passive reconstructive hardware into active therapeutic interfaces. Founded by Dr. Chad Gordon, a Johns Hopkins neuroplastic surgeon, CraniUS aims to address the challenge of delivering life-saving medicinal therapies to the brain, which are often hindered by the BBB. The Series B round includes $19 million from private investors and $1 million in non-dilutive funding from the State of Maryland, bringing the total capital raised by CraniUS to approximately $40 million.
Why It's Important?
The development of the NeuroPASS platform represents a significant advancement in the treatment of neurological diseases and brain cancer. By enabling direct therapeutic access to the brain, this technology could potentially overcome a major barrier in medical treatment that has persisted for decades. The ability to bypass the BBB could lead to more effective treatments for patients suffering from debilitating neurological conditions, offering new hope where traditional methods have failed. This innovation not only has the potential to improve patient outcomes but also positions CraniUS as a leader in the neurotechnology field, potentially influencing future research and development in brain health and treatment.
What's Next?
With the new funding, CraniUS plans to support operations into 2027, focusing on regulatory submissions, manufacturing scale-up, and product testing towards future commercialization of the NeuroPASS platform. The company holds 15 domestic patents and numerous international patents, which will support its long-term product roadmap. As the platform progresses through regulatory review, CraniUS will likely engage with healthcare providers and industry experts to prepare for eventual market entry. The success of this platform could prompt further investment and interest in neurotechnology solutions that address the challenges posed by the BBB.
